Nanotechnology for boosting ovarian cancer immunotherapy.
Adoptive cell therapy
Chimeric antigen receptor T-cell therapy
Clinical trials
Immune checkpoint blockade
Myeloid-derived suppressor cells
Ovarian cancer
Photodynamic therapy
Photothermal therapy
Regulatory T cells
Tumor-associated macrophages
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
04
08
2024
accepted:
28
08
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Ovarian cancer, often referred to as the "silent killer," is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to its ambiguous and frequently occurring clinical symptoms. Ovarian cancer leads to more deaths than any other cancer of the female reproductive system. The main reasons for the high mortality rates include delayed diagnosis and resistance to treatment. As a result, there is an urgent need for improved diagnostic and treatment options for ovarian cancer. The standard treatments typically involve debulking surgery along with platinum-based chemotherapies. Among patients with advanced-stage cancer who initially respond to current therapies, 50-75% experience a recurrence. Recently, immunotherapy-based approaches to enhance the body's immune response to combat tumor growth have shown promise. Immune checkpoint inhibitors have shown promising results in treating other types of tumors. However, in ovarian cancer, only a few of these inhibitors have been effective because the tumor's environment suppresses the immune system and creates barriers for treatment. This hampers the effectiveness of existing immunotherapies. Nonetheless, advanced immunotherapy techniques and delivery systems based on nanotechnology hold promise for overcoming these challenges.
Identifiants
pubmed: 39402681
doi: 10.1186/s13048-024-01507-z
pii: 10.1186/s13048-024-01507-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Subventions
Organisme : NCI NIH HHS
ID : R01CA256724
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA256724
Pays : United States
Organisme : NIH HHS
ID : SC1CA193758
Pays : United States
Organisme : American Cancer Society
ID : CHERC-MSI-21-166-01-CHERC-MSI
Organisme : U.S. Department of Defense
ID : W81XWH1810429
Informations de copyright
© 2024. The Author(s).
Références
Colombo I, Karakasis K, Suku S, Oza AM. Chasing Immune checkpoint inhibitors in Ovarian Cancer: Novel combinations and Biomarker Discovery. Cancers (Basel) 2023, 15(12).
Corradetti B, Pisano S, Conlan RS, Ferrari M. Nanotechnology and immunotherapy in ovarian Cancer: tracing New landscapes. J Pharmacol Exp Ther. 2019;370(3):636–46.
pmcid: 6806629
doi: 10.1124/jpet.118.254979
pubmed: 30737357
Bhavsar D, Raguraman R, Kim D, Ren X, Munshi A, Moore K, Sikavitsas V, Ramesh R. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J Ovarian Res. 2024;17(1):113.
pmcid: 11127348
doi: 10.1186/s13048-024-01417-0
pubmed: 38796525
Yang Y, Zhao T, Chen Q, Li Y, Xiao Z, Xiang Y, Wang B, Qiu Y, Tu S, Jiang Y, et al. Nanomedicine strategies for Heating Cold Ovarian Cancer (OC): next evolution in Immunotherapy of OC. Adv Sci (Weinh). 2022;9(28):e2202797.
doi: 10.1002/advs.202202797
pubmed: 35869032
Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomed. 2014;9:467–83.
Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982–7015.
doi: 10.1021/acsnano.1c04996
pubmed: 34181394
Figueiras A, Domingues C, Jarak I, Santos AI, Parra A, Pais A, Alvarez-Lorenzo C, Concheiro A, Kabanov A, Cabral H et al. New advances in Biomedical Application of Polymeric Micelles. Pharmaceutics 2022, 14(8).
McFadden M, Singh SK, Kinnel B, Varambally S, Singh R. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023;16(1):220.
pmcid: 10662420
doi: 10.1186/s13048-023-01308-w
pubmed: 37990267
McFadden M, Singh SK, Oprea-Ilies G, Singh R. Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. Cancers (Basel) 2021, 13(21).
Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, Laoui D. Dendritic cell vaccines: a Promising Approach in the fight against Ovarian Cancer. Cancers (Basel) 2022, 14(16).
Cheng S, Xu C, Jin Y, Li Y, Zhong C, Ma J, Yang J, Zhang N, Li Y, Wang C, et al. Artificial Mini dendritic cells boost T cell-based immunotherapy for ovarian Cancer. Adv Sci (Weinh). 2020;7(7):1903301.
doi: 10.1002/advs.201903301
pubmed: 32274314
Zhang X, He T, Li Y, Chen L, Liu H, Wu Y, Guo H. Dendritic cell vaccines in Ovarian Cancer. Front Immunol. 2020;11:613773.
doi: 10.3389/fimmu.2020.613773
pubmed: 33584699
Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI et al. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer 2023, 11(11).
Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, Mor G. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am J Reprod Immunol. 2011;65(6):597–609.
pmcid: 3082607
doi: 10.1111/j.1600-0897.2010.00968.x
pubmed: 21241402
Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012;72(7):1683–93.
pmcid: 3319850
doi: 10.1158/0008-5472.CAN-11-3160
pubmed: 22307839
Chianese-Bullock KA, Irvin WP Jr., Petroni GR, Murphy C, Smolkin M, Olson WC, Coleman E, Boerner SA, Nail CJ, Neese PY, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008;31(4):420–30.
doi: 10.1097/CJI.0b013e31816dad10
pubmed: 18391753
Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, et al. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019;8(10):4678–87.
pmcid: 6712444
doi: 10.1002/cam4.2378
pubmed: 31274231
Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian Cancer patients. Clin Cancer Res. 2018;24(13):3014–25.
pmcid: 6030477
doi: 10.1158/1078-0432.CCR-17-2499
pubmed: 29545464
Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009;37(Database issue):D816–819.
doi: 10.1093/nar/gkn673
pubmed: 18838390
Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, Odunsi K. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017;145(3):420–5.
pmcid: 5497581
doi: 10.1016/j.ygyno.2017.03.509
pubmed: 28392127
Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(31):12837–42.
pmcid: 1937553
doi: 10.1073/pnas.0703342104
pubmed: 17652518
Jiang A, He W, Yao Y. Editorial: overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine. Front Oncol. 2024;14:1406244.
pmcid: 11026582
doi: 10.3389/fonc.2024.1406244
pubmed: 38646437
Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, Bharti V, Schulman JA, Becker KW, Roth EW, Christov PP, et al. A Cancer Nanovaccine for Co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano. 2024;18(9):6845–62.
pmcid: 10919087
doi: 10.1021/acsnano.3c04471
pubmed: 38386282
Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, et al. Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. Br J Cancer. 2019;120(4):424–34.
pmcid: 6461863
doi: 10.1038/s41416-019-0384-y
pubmed: 30718808
Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology. 2018;7(12):e1502905.
pmcid: 6279323
doi: 10.1080/2162402X.2018.1502905
pubmed: 30524900
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: adjuvant, combination, and Neoadjuvant. Front Immunol. 2020;11:577869.
pmcid: 7572849
doi: 10.3389/fimmu.2020.577869
pubmed: 33123161
Kumar S, Acharya S, Karthikeyan M, Biswas P, Kumari S. Limitations and potential of immunotherapy in ovarian cancer. Front Immunol. 2023;14:1292166.
doi: 10.3389/fimmu.2023.1292166
pubmed: 38264664
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Maenpaa J, et al. Atezolizumab, Bevacizumab, and Chemotherapy for newly diagnosed stage III or IV ovarian Cancer: placebo-controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842–55.
pmcid: 8189598
doi: 10.1200/JCO.21.00306
pubmed: 33891472
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, et al. Atezolizumab Combined with Bevacizumab and Platinum-based therapy for platinum-sensitive ovarian Cancer: placebo-controlled Randomized Phase III ATALANTE/ENGOT-ov29 trial. J Clin Oncol. 2023;41(30):4768–78.
pmcid: 10602539
doi: 10.1200/JCO.23.00529
pubmed: 37643382
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O’Malley DM, Lorusso D, Westin SN, Safra T, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021;31(12):1589–94.
pmcid: 8666815
doi: 10.1136/ijgc-2021-002933
pubmed: 34593565
Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as maintenance treatment in patients with newly diagnosed ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952–64.
pmcid: 9746782
doi: 10.1200/JCO.22.01003
pubmed: 35658487
Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. Cancers (Basel) 2021, 13(24).
Zamarin D, Burger RA, Sill MW, Powell DJ Jr., Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, et al. Randomized phase II trial of Nivolumab Versus Nivolumab and Ipilimumab for recurrent or persistent ovarian Cancer: an NRG Oncology Study. J Clin Oncol. 2020;38(16):1814–23.
pmcid: 7255977
doi: 10.1200/JCO.19.02059
pubmed: 32275468
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, et al. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncol. 2023;19(23):1577–91.
doi: 10.2217/fon-2023-0246
pubmed: 37334673
Aichen Z, Kun W, Xiaochun S, Lingling T. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p. Apoptosis. 2021;26(5–6):348–60.
doi: 10.1007/s10495-021-01674-0
pubmed: 33974163
Zuo Y, Zheng W, Liu J, Tang Q, Wang SS, Yang XS. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 2020;67(1):93–101.
doi: 10.4149/neo_2019_190202N106
pubmed: 31777260
Deng H, Zhang Z. The application of nanotechnology in immune checkpoint blockade for cancer treatment. J Control Release. 2018;290:28–45.
doi: 10.1016/j.jconrel.2018.09.026
pubmed: 30287266
Nie W, He Y, Mi X, He S, Chen J, Zhang Y, Wang B, Zheng S, Qian Z, Gao X. Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer. Bioact Mater. 2024;39:239–54.
pmcid: 11145080
pubmed: 38832303
Teo PY, Yang C, Whilding LM, Parente-Pereira AC, Maher J, George AJ, Hedrick JL, Yang YY, Ghaem-Maghami S. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. Adv Healthc Mater. 2015;4(8):1180–9.
doi: 10.1002/adhm.201500089
pubmed: 25866054
Zhang XW, Wu YS, Xu TM, Cui MH. CAR-T cells in the treatment of ovarian Cancer: a promising cell therapy. Biomolecules 2023, 13(3).
Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. Gynecol Oncol. 2024;180:1–5.
Harris FR, Zhang P, Yang L, Hou X, Leventakos K, Weroha SJ, Vasmatzis G, Kovtun IV. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Mol Oncol. 2019;13(2):132–52.
doi: 10.1002/1878-0261.12414
pubmed: 30499260
Cutri-French C, Nasioudis D, George E, Tanyi JL. CAR-T cell therapy in Ovarian Cancer: where are we now? Diagnostics (Basel) 2024, 14(8).
Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72(2):409–25.
doi: 10.1007/s00262-022-03238-w
pubmed: 35925286
Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20(3):633–43.
doi: 10.1038/mt.2011.256
pubmed: 22127019
Haas AR, Tanyi JL, O’Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et al. Phase I study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid cancers. Mol Ther. 2019;27(11):1919–29.
pmcid: 6838875
doi: 10.1016/j.ymthe.2019.07.015
pubmed: 31420241
Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, et al. Development of Anti-human Mesothelin-targeted chimeric Antigen receptor Messenger RNA-Transfected peripheral blood lymphocytes for ovarian Cancer therapy. Hum Gene Ther. 2018;29(5):614–25.
pmcid: 5930796
doi: 10.1089/hum.2017.080
pubmed: 29334771
Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J, Li Q. Therapeutic strategies targeting folate receptor alpha for ovarian cancer. Front Immunol. 2023;14:1254532.
pmcid: 10499382
doi: 10.3389/fimmu.2023.1254532
pubmed: 37711615
Heo YA. Mirvetuximab Soravtansine: first approval. Drugs. 2023;83(3):265–73.
doi: 10.1007/s40265-023-01834-3
pubmed: 36656533
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, et al. Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian Cancer with high folate receptor alpha expression: results from the SORAYA Study. J Clin Oncol. 2023;41(13):2436–45.
pmcid: 10150846
doi: 10.1200/JCO.22.01900
pubmed: 36716407
Mi J, Ye Q, Min Y. Advances in Nanotechnology Development to Overcome Current roadblocks in CAR-T therapy for solid tumors. Front Immunol. 2022;13:849759.
pmcid: 8983935
doi: 10.3389/fimmu.2022.849759
pubmed: 35401561
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401.
doi: 10.1038/nature18300
pubmed: 27281205
Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Woll S, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446–53.
doi: 10.1126/science.aay5967
pubmed: 31896660
Chan JD, von Scheidt B, Zeng B, Oliver AJ, Davey AS, Ali AI, Thomas R, Trapani JA, Darcy PK, Kershaw MH, et al. Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells. Clin Transl Immunol. 2020;9(7):e1157.
doi: 10.1002/cti2.1157
Anko M, Kobayashi Y, Banno K, Aoki D. Current status and prospects of Immunotherapy for Gynecologic Melanoma. J Pers Med 2021, 11(5).
Kaur P, Singh SK, Mishra MK, Singh S, Singh R. Promising combinatorial therapeutic strategies against Non-small Cell Lung Cancer. Cancers (Basel) 2024, 16(12).
Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193–204.
doi: 10.1158/1078-0432.CCR-13-1536
pubmed: 24036854
Qin Y, Song QG, Zhang ZR, Liu J, Fu Y, He Q, Liu J. Ovarian tumor targeting of docetaxel-loaded liposomes mediated by luteinizing hormone-releasing hormone analogues. In vive distribution in nude mice. Arzneimittelforschung. 2008;58(10):529–34.
pubmed: 19025064
Nukolova NV, Oberoi HS, Cohen SM, Kabanov AV, Bronich TK. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011;32(23):5417–26.
pmcid: 3255291
doi: 10.1016/j.biomaterials.2011.04.006
pubmed: 21536326
Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, Sanchez E, Xing L, Cheng HR, Luo J, et al. OA02 peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 2012;72(8):2100–10.
pmcid: 3343697
doi: 10.1158/0008-5472.CAN-11-3883
pubmed: 22396491
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.
doi: 10.1038/nm1093
pubmed: 15322536
Lecker LSM, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C, Novak M, McDermott J, et al. TGFBI Production by macrophages contributes to an immunosuppressive microenvironment in Ovarian Cancer. Cancer Res. 2021;81(22):5706–19.
pmcid: 9397609
doi: 10.1158/0008-5472.CAN-21-0536
pubmed: 34561272
Kang Y, Flores L, Ngai HW, Cornejo YR, Haber T, McDonald M, Moreira DF, Gonzaga JM, Abidi W, Zhang Y, et al. Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7/8 agonist to repolarize ovarian tumors’ Microenvironment. Bioconjug Chem. 2021;32(8):1581–92.
doi: 10.1021/acs.bioconjchem.1c00139
pubmed: 34289694
Haber T, Cornejo YR, Aramburo S, Flores L, Cao P, Liu A, Mooney R, Gilchrist M, Tirughana R, Nwokafor U, et al. Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles. Proc Natl Acad Sci U S A. 2020;117(33):19737–45.
pmcid: 7443897
doi: 10.1073/pnas.1917424117
pubmed: 32732430
Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev. 2011;241(1):260–8.
pmcid: 3077798
doi: 10.1111/j.1600-065X.2011.01018.x
pubmed: 21488902
Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci. 2018;1417(1):104–15.
doi: 10.1111/nyas.13625
pubmed: 29566262
Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–18.
doi: 10.1038/cr.2016.151
pubmed: 27995907
Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016;5(3):e1090075.
doi: 10.1080/2162402X.2015.1090075
pubmed: 27141347
Shams F, Golchin A, Azari A, Mohammadi Amirabad L, Zarein F, Khosravi A, Ardeshirylajimi A. Nanotechnology-based products for cancer immunotherapy. Mol Biol Rep. 2022;49(2):1389–412.
doi: 10.1007/s11033-021-06876-y
pubmed: 34716502
Sacchetti C, Rapini N, Magrini A, Cirelli E, Bellucci S, Mattei M, Rosato N, Bottini N, Bottini M. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem. 2013;24(6):852–8.
doi: 10.1021/bc400070q
pubmed: 23682992
Ou W, Thapa RK, Jiang L, Soe ZC, Gautam M, Chang JH, Jeong JH, Ku SK, Choi HG, Yong CS, et al. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release. 2018;281:84–96.
doi: 10.1016/j.jconrel.2018.05.018
pubmed: 29777794
Wilson AL, Moffitt LR, Wilson KL, Bilandzic M, Wright MD, Gorrell MD, Oehler MK, Plebanski M, Stephens AN. DPP4 inhibitor sitagliptin enhances lymphocyte recruitment and prolongs survival in a syngeneic ovarian Cancer Mouse Model. Cancers (Basel) 2021, 13(3).
Mabuchi S, Sasano T, Komura N. Targeting myeloid-derived suppressor cells in Ovarian Cancer. Cells 2021, 10(2).
Xu T, Liu Z, Huang L, Jing J, Liu X. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy. Front Immunol. 2022;13:1057850.
pmcid: 9751906
doi: 10.3389/fimmu.2022.1057850
pubmed: 36532066
Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 2020;69(12):2477–99.
pmcid: 11027471
doi: 10.1007/s00262-020-02628-2
pubmed: 32561967
Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, Yoshioka Y, Koshiyama M, Konishi I. Expression of vascular endothelial growth factor in Ovarian Cancer inhibits Tumor immunity through the Accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–99.
doi: 10.1158/1078-0432.CCR-16-0387
pubmed: 27401249
Horikawa N, Abiko K, Matsumura N, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Taki M, Ukita M, Hosoe Y, et al. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br J Cancer. 2020;122(6):778–88.
pmcid: 7078258
doi: 10.1038/s41416-019-0725-x
pubmed: 31932754
Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun. 2018;9(1):1685.
pmcid: 5923228
doi: 10.1038/s41467-018-03966-7
pubmed: 29703902
Kielbik M, Przygodzka P, Szulc-Kielbik I, Klink M. Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189003.
doi: 10.1016/j.bbcan.2023.189003
pubmed: 37863122
Okla K. Myeloid-derived suppressor cells (MDSCs) in ovarian Cancer-looking back and Forward. Cells 2023, 12(14).
Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-Induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian Cancer. Cancer Res. 2018;78(7):1779–91.
pmcid: 5882589
doi: 10.1158/0008-5472.CAN-17-2460
pubmed: 29374065
Alexander ET, Minton AR, Peters MC, van Ryn J, Gilmour SK. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget. 2016;7(51):85291–305.
pmcid: 5356737
doi: 10.18632/oncotarget.13300
pubmed: 27852034
Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest. 2009;119(8):2231–44.
pmcid: 2719935
pubmed: 19620771
Nizzero S, Ziemys A, Ferrari M. Transport barriers and oncophysics in Cancer Treatment. Trends Cancer. 2018;4(4):277–80.
pmcid: 6441955
doi: 10.1016/j.trecan.2018.02.008
pubmed: 29606312
Dai J, Xu M, Wang Q, Yang J, Zhang J, Cui P, Wang W, Lou X, Xia F, Wang S. Cooperation therapy between anti-growth by photodynamic-AIEgens and anti-metastasis by small molecule inhibitors in ovarian cancer. Theranostics. 2020;10(5):2385–98.
pmcid: 7019153
doi: 10.7150/thno.41708
pubmed: 32104509
Wu Y, Yang Y, Lv X, Gao M, Gong X, Yao Q, Liu Y. Nanoparticle-based combination therapy for ovarian Cancer. Int J Nanomed. 2023;18:1965–87.
doi: 10.2147/IJN.S394383
Schumann C, Taratula O, Khalimonchuk O, Palmer AL, Cronk LM, Jones CV, Escalante CA, Taratula O. ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression. Nanomedicine. 2015;11(8):1961–70.
doi: 10.1016/j.nano.2015.07.005
pubmed: 26238076
Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm. 2006;326(1–2):174–81.
doi: 10.1016/j.ijpharm.2006.07.012
pubmed: 16930882
Michy T, Massias T, Bernard C, Vanwonterghem L, Henry M, Guidetti M, Royal G, Coll JL, Texier I, Josserand V et al. Verteporfin-loaded lipid nanoparticles improve ovarian Cancer Photodynamic Therapy in Vitro and in vivo. Cancers (Basel) 2019, 11(11).
Mir Y, Elrington SA, Hasan T. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine. 2013;9(7):1114–22.
doi: 10.1016/j.nano.2013.02.005
pubmed: 23485748
Zhao J, Zhang L, Qi Y, Liao K, Wang Z, Wen M, Zhou D. NIR Laser Responsive nanoparticles for Ovarian Cancer targeted combination therapy with Dual-Modal Imaging Guidance. Int J Nanomed. 2021;16:4351–69.
doi: 10.2147/IJN.S299376
Sanchez-Ramirez DR, Dominguez-Rios R, Juarez J, Valdes M, Hassan N, Quintero-Ramos A, Del Toro-Arreola A, Barbosa S, Taboada P, Topete A, et al. Biodegradable photoresponsive nanoparticles for chemo-, photothermal- and photodynamic therapy of ovarian cancer. Mater Sci Eng C Mater Biol Appl. 2020;116:111196.
doi: 10.1016/j.msec.2020.111196
pubmed: 32806317
Malacarne MC, Caruso E, Gariboldi MB, Marras E, Della Bitta G, Santoro O, Simm A, Li R, Ferguson CTJ. Evaluation of nanoparticles covalently bound with BODIPY for their photodynamic therapy applicability. Int J Mol Sci 2024, 25(6).
Overchuk M, Weersink RA, Wilson BC, Zheng G. Photodynamic and photothermal therapies: Synergy opportunities for Nanomedicine. ACS Nano. 2023;17(9):7979–8003.
pmcid: 10173698
doi: 10.1021/acsnano.3c00891
pubmed: 37129253
Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G, Liu Y, Cheng J, Wang Z, Wang S, et al. Cancer-Erythrocyte Hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian Cancer. ACS Nano. 2021;15(12):19756–70.
doi: 10.1021/acsnano.1c07180
pubmed: 34860006